Skip to content
Pierre Country
    • Homepage
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Author: Larimar Therapeutics

Posted Date:

June 29, 2026
  • Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

    Larimar Therapeutics
    June 29, 2026
  • Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

    Larimar Therapeutics
    June 26, 2026
  • Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update

    Larimar Therapeutics
    May 14, 2026
  • Larimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s Ataxia

    Larimar Therapeutics
    April 30, 2026
  • Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

    Larimar Therapeutics
    March 19, 2026
  • Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

    Larimar Therapeutics
    March 4, 2026
  • Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

    Larimar Therapeutics
    February 25, 2026
  • Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

    Larimar Therapeutics
    February 25, 2026
  • Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

    Larimar Therapeutics
    February 24, 2026